Literature DB >> 22320316

Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway.

P Møller1, L Maehle, A Vabø, N Clark, P Sun, S A Narod.   

Abstract

Incidence rates of breast cancer among women with a BRCA1 mutation vary according to their reproductive histories and country of residence. To measure cancer incidence, it is best to follow-up cohort of healthy women prospectively. We followed up a cohort of 675 women with a BRCA1 mutation who did not have breast or ovarian cancer before inclusion and who had a normal clinical examination and mammography at first visit. After a mean of 7.1 years, 98 incident cases of breast cancer were recorded in the cohort. Annual cancer incidence rates were calculated, and based on these, a penetrance curve was constructed. The average annual cancer risk for the Norwegian women from age 25 to 70 was 2.0%. Founder mutations had lower incidence rate (1.7%) than less frequent mutations (2.5%) (p = 0.03). The peak incidence (3.1% annual risk) was observed in women from age 50 to 59. The age-specific annual incidence rates and penetrance estimate were compared with published figures for women from North America and from Poland. The risk of breast cancer to age 70 was estimated to be 61% for women from Norway, compared with 55% for women from Poland and 69% for women from North America.
© 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22320316     DOI: 10.1111/j.1399-0004.2012.01855.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  9 in total

Review 1.  Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

Authors:  Tuya Pal; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

2.  BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.

Authors:  Henriette Roed Nielsen; Mef Nilbert; Janne Petersen; Steen Ladelund; Mads Thomassen; Inge Søkilde Pedersen; Thomas V O Hansen; Anne-Bine Skytte; Åke Borg; Christina Therkildsen
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

3.  Tumour characteristics and survival in familial breast cancer prospectively diagnosed by annual mammography.

Authors:  Pål Møller; Kukatharmini Tharmaratnam; Anthony Howell; Paula Stavrinos; Sarah Sampson; Andrew Wallace; Anthony J Maxwell; Anne Irene Hagen; D Gareth Evans
Journal:  Breast Cancer Res Treat       Date:  2015-06-03       Impact factor: 4.872

4.  Ten modifiers of BRCA1 penetrance validated in a Norwegian series.

Authors:  Cecilie Heramb; Per Olaf Ekstrøm; Kukatharmini Tharmaratnam; Eivind Hovig; Pål Møller; Lovise Mæhle
Journal:  Hered Cancer Clin Pract       Date:  2015-05-30       Impact factor: 2.857

Review 5.  Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States.

Authors:  Deborah Cragun; Tuya Pal
Journal:  ISRN Oncol       Date:  2013-12-22

6.  The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation.

Authors:  Pål Møller; Astrid Stormorken; Marit Muri Holmen; Anne Irene Hagen; Anita Vabø; Lovise Mæhle
Journal:  Breast Cancer Res Treat       Date:  2014-03-12       Impact factor: 4.872

7.  Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database.

Authors:  Pål Møller; Toni T Seppälä; Inge Bernstein; Elke Holinski-Feder; Paulo Sala; D Gareth Evans; Annika Lindblom; Finlay Macrae; Ignacio Blanco; Rolf H Sijmons; Jacqueline Jeffries; Hans F A Vasen; John Burn; Sigve Nakken; Eivind Hovig; Einar Andreas Rødland; Kukatharmini Tharmaratnam; Wouter H de Vos Tot Nederveen Cappel; James Hill; Juul T Wijnen; Mark A Jenkins; Kate Green; Fiona Lalloo; Lone Sunde; Miriam Mints; Lucio Bertario; Marta Pineda; Matilde Navarro; Monika Morak; Laura Renkonen-Sinisalo; Mev Dominguez Valentin; Ian M Frayling; John-Paul Plazzer; Kirsi Pylvanainen; Maurizio Genuardi; Jukka-Pekka Mecklin; Gabriela Moeslein; Julian R Sampson; Gabriel Capella
Journal:  Gut       Date:  2017-07-28       Impact factor: 23.059

8.  Identifying Needs: a Qualitative Study of women's Experiences Regarding Rapid Genetic Testing for Hereditary Breast and Ovarian Cancer in the DNA BONus Study.

Authors:  Mirjam Tonheim Augestad; Hildegunn Høberg-Vetti; Cathrine Bjorvatn; Ragnhild Johanne Tveit Sekse
Journal:  J Genet Couns       Date:  2016-07-28       Impact factor: 2.537

9.  Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.

Authors:  Alexander Liede; Carol A Mansfield; Kelly A Metcalfe; Melanie A Price; Carrie Snyder; Henry T Lynch; Sue Friedman; Justyna Amelio; Joshua Posner; Steven A Narod; Geoffrey J Lindeman; D Gareth Evans
Journal:  Breast Cancer Res Treat       Date:  2017-06-17       Impact factor: 4.872

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.